,99, 100, 101, 102, 103 Of interest, in pancreatic adenocarcinoma, greater diversity in the peripheral blood TCR repertoire was associated with improved survival in patients receiving anti-CTLA-4 therapy, but not in those receiving anti-PD-1 therapy,99 consistently with the common hypothesis that CTLA-4 blockade mainly promotes naive T-cell priming while PD-(L)1 blockade acts on antigen-experienced T cells.4 The gene discussed is CTLA4; the disease is pancreatic adenocarcinoma.